SCHEMBL4349850

SCHEMBL4349850

CC(C)CN(C[C@H](O)[C@H](Cc1ccc(OCc2ccccn2)cc1)NC(=O)O)S(=O)(=O)c1ccc(N)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLNR O43193 1/20 0.54
ABCB11 O95342 1/20 0.54
LMNA P02545 1/20 0.54
CTSD P07339 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP3A5 P20815 1/20 0.54
CNR1 P21554 1/20 0.54
TBXAS1 P24557 1/20 0.54
ADRA1A P35348 1/20 0.54
ABCB1 P08183 1/20 0.51
KCNE1 P15382 1/20 0.51
KCNQ1 P51787 1/20 0.51
KCNH2 Q12809 1/20 0.51
SCN5A Q14524 1/20 0.51
KCND3 Q9UK17 1/20 0.51
SPPL2A Q8TCT8 1/20 0.50
MAOB P27338 1/20 0.49
ADAMTS4 O75173 1/20 0.48
MMP2 P08253 1/20 0.48
MMP13 P45452 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4349846 1.00 MLNR (0.54) MLNRABCB11LMNACTSDCYP3A4
SCHEMBL4356243 0.91 SPPL2A (0.48) SPPL2AMAOBADAMTS4MMP2MMP13
SCHEMBL4356237 0.91 SPPL2A (0.48) SPPL2AMAOBADAMTS4MMP2MMP13
SCHEMBL4346689 0.90 MLNR (0.60) MLNRABCB11LMNACTSDCYP3A4
SCHEMBL4346692 0.90 MLNR (0.60) MLNRABCB11LMNACTSDCYP3A4
SCHEMBL4349865 0.87 ABCB1 (0.56) MLNRABCB11LMNACTSDCYP3A4
SCHEMBL4349870 0.87 ABCB1 (0.56) MLNRABCB11LMNACTSDCYP3A4
SCHEMBL4351141 0.86 ABCB1 (0.58) MLNRABCB11LMNACTSDCYP3A4
SCHEMBL4351144 0.86 ABCB1 (0.58) MLNRABCB11LMNACTSDCYP3A4
SCHEMBL1094790 0.84 MLNR (0.67) MLNRABCB11LMNACTSDCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455497-B2 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-04 US disclosed
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED 2009-11-05 US disclosed
EP-1194404-B1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMA (US) 2006-05-03 EP disclosed
US-6878728-B1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICAL INCORPORATED (US) 2005-04-12 US disclosed
US-20040122000-A1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED. 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122000-A1 Inhibitors of aspartyl protease SPINT2, DNPEP, PRSS1 MLNR 4166/4885ABCB11 1940/4885LMNA 4130/4885
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE SPINT2, DNPEP, PRSS1 MLNR 4166/4885ABCB11 1940/4885LMNA 4130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.